A Phase 2/3, Open-Label Study of t and Childrenhe Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1

Administered By

Awarded By

Contributors

Start/End

  • January 31, 2017 - May 31, 2023